BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks
Bests Imbruvica In CLL
BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic lymphoma, marking the first time a rival BTK inhibitor has bested the same-class standard of care in this setting, and lifting the shares of other Chinese biotechs.
You may also be interested in...
Keeping Track: New Claims For Tukysa, Brukinsa; US FDA Wants More Patients To Support Donanemab, Pediatric Airsupra Bids
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms
Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.
ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets
Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.